Fenofibrate/simvastatin

From WikiProjectMed
Jump to navigation Jump to search

Fenofibrate/simvastatin
Combination of
FenofibrateFibrate
SimvastatinStatin
Clinical data
Trade namesCholib
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1] It contains fenofibrate and simvastatin.[1]

It was approved for use in the European Union in August 2013.[1]

Medical uses

Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.[1]

Adverse effects

See also: Fenofibrate § Adverse_effects, and Simvastatin § Adverse_effects

References

  1. ^ a b c d e "Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading

External links

  • "Fenofibrate". Drug Information Portal. U.S. National Library of Medicine.
  • "Simvastatin". Drug Information Portal. U.S. National Library of Medicine.


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Fenofibrate/simvastatin"